Pulmonary Hypertension Treatment Options

Once pulmonary hypertension is suspected or confirmed, a common question follows quickly: what is the treatment? There isn’t a single answer. Pulmonary hypertension treatment is chosen based on which underlying category, or WHO group, best explains the elevated pressure, and the right approach for one group can be unhelpful or inappropriate for another. This page looks more closely at how that decision is made and what the major treatment categories involve. It is general education, not a substitute for an individualized treatment plan from a physician familiar with your specific case.

Why Treatment Starts With the WHO Group, Not the Number

A pulmonary artery pressure reading by itself does not tell a physician what to do next. Two patients with a similar degree of elevated pressure can need entirely different treatment plans depending on what is driving it. This is why pulmonary hypertension is organized into five World Health Organization (WHO) groups based on underlying mechanism, and why establishing the group is the first step before any treatment decision is made.

The Five WHO Groups at a Glance

Group 1: Pulmonary Arterial Hypertension (PAH)

The small pulmonary arteries themselves become narrowed, thickened, or stiff. This is the group treated with dedicated PAH-specific medications.

Group 2: Left Heart Disease

Pulmonary pressure rises as a downstream effect of conditions affecting the left side of the heart, such as heart failure or valve disease.

Group 3: Lung Disease or Chronic Low Oxygen

Long-standing lung conditions, such as COPD or interstitial lung disease, or chronic low blood oxygen, lead to elevated pulmonary pressure over time.

Group 4: Chronic Thromboembolic Disease (CTEPH)

Blood clots in the lung arteries that do not fully resolve instead scar and narrow the vessels, a group with distinct surgical and interventional options.

A fifth group, encompassing pulmonary hypertension with unclear or multifactorial mechanisms, also exists, though it is less common. Because groups 1 and 4 have treatments that are meaningfully different from groups 2, 3, and 5, misclassifying a patient’s group can lead to treatment that does not help, and in some cases could be harmful.

Confirming the Group Before Treatment Begins

Right heart catheterization plays a central role here. Because echocardiography only estimates pulmonary pressures, right heart catheterization, which measures pressures directly using a thin catheter guided into the right side of the heart and pulmonary arteries, is the reference-standard test used to confirm the diagnosis. It also provides hemodynamic detail that helps a specialist establish which WHO group most likely applies, often alongside pulmonary function testing, imaging, and other targeted testing.

From Suspicion to Treatment Decision

1. 01→Clinical Suspicion or Screening FindingSymptoms or an echocardiogram raise concern for elevated pulmonary artery pressure.↓
2. 02Right Heart CatheterizationDirect pressure measurement confirms the diagnosis and provides hemodynamic detail relevant to classification.↓
3. 03→Group-Specific WorkupAdditional testing, such as pulmonary function testing, chest imaging, or a ventilation/perfusion scan, helps identify the underlying cause.↓
4. 04Treatment Plan SelectedThe confirmed WHO group, combined with disease severity and individual patient factors, guides which treatment category is appropriate.

Starting a PAH-specific medication without this confirmatory workup is generally avoided, given how specific, and often costly, these therapies are, and because they are not interchangeable across groups.

Group 1: Pulmonary Arterial Hypertension Medications

Group 1 PAH is the category with a dedicated family of medications, developed specifically to relax and, in some cases, help remodel the small pulmonary arteries. These medications work through several distinct biological pathways, and a specialist often combines drugs from more than one class depending on disease severity.

Newer add-on therapies that work through additional biological pathways relevant to PAH have also become part of the treatment landscape in recent years, generally used alongside, rather than instead of, these established classes. The specific medications, combinations, doses, and route of administration are individualized decisions made by a PAH specialist based on disease severity, how a patient responds over time, and other health factors. This page describes categories in general educational terms; it is not a guide to selecting or dosing a specific medication.

Groups 2 and 3: Treating the Underlying Heart or Lung Disease

For pulmonary hypertension that develops as a downstream consequence of left heart disease (group 2) or chronic lung disease and low oxygen (group 3), the treatment approach looks different. PAH-specific medications are generally not appropriate for these groups, and in some circumstances can potentially worsen outcomes, which is part of why accurate group classification matters so much before treatment begins.

Oxygen Therapy When Hypoxemia Is Present

Regardless of which WHO group applies, supplemental oxygen is added whenever testing confirms a significant, sustained drop in blood oxygen levels. Chronic low oxygen adds strain to the pulmonary arteries and the heart’s right side, so correcting it where present is a widely applicable part of care. Oxygen therapy decisions are based on measured oxygen levels from testing, not assumed from symptoms alone.

Group 4: CTEPH’s Distinct Treatment Path

Chronic thromboembolic pulmonary hypertension (CTEPH) stands apart because, unlike the other groups, it can potentially be addressed with a surgical or catheter-based procedure rather than medication alone. When unresolved blood clots in the lung arteries have scarred and narrowed the vessels, a specialized surgical procedure called pulmonary endarterectomy can, in appropriate candidates, remove that chronic clot material directly. For patients who are not surgical candidates, or who have residual disease after surgery, catheter-based balloon pulmonary angioplasty and specific CTEPH-directed medication are treatment options. Because CTEPH evaluation and treatment involve specialized decision-making, our CTEPH page covers this pathway in more detail.

Why Individualization Matters So Much Here

Pulmonary hypertension treatment decisions depend on far more than the WHO group alone. Disease severity, how a patient responds to an initial treatment, other coexisting medical conditions, and practical factors around route of administration and monitoring all factor into a specialist’s recommendation. Two patients within the same WHO group can reasonably end up on different treatment plans. This page is intended to help patients understand the general landscape of pulmonary hypertension treatment, not to guide self-selection of a specific therapy.

When to Talk to a Specialist

If you have been told you may have pulmonary hypertension, or you have a confirmed diagnosis and questions about your treatment options, that conversation belongs with a physician experienced in pulmonary vascular disease. VitalAir Sleep & Lung Center, based in Frisco, Texas and serving patients across the North Dallas-Fort Worth area, evaluates patients with suspected or confirmed pulmonary hypertension and coordinates the testing needed to identify the underlying cause and discuss an appropriate, individualized treatment approach.